Pandemic Response Lessons
Lessons learned from the pandemic can advance future biologic drug development and manufacturing.
How have biopharma companies responded and adjusted to pandemic issues? What lessons learned under fire may lead to more effective and efficient bioprocessing practices going forward? Eric Langer, managing partner, BioPlan Associates, Inc., shared research and expert insight in Delivering on the Promise: Overcoming Biopharma Development and Manufacturing Challenges.
This presentation and Q&A with BioPharm International editors was recorded during the 2020 Bio/Pharma Virtual Congress on Nov. 11, 2020.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
